|
The Treatment of Children and Adolescents with Treatment-Resistant Depression Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on The Treatment of Children and Adolescents with Treatment-Resistant Depression conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. The Treatment of Children and Adolescents with Treatment-Resistant Depression Clinical research trials and The Treatment of Children and Adolescents with Treatment-Resistant Depression healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including The Treatment of Children and Adolescents with Treatment-Resistant Depression. The Treatment of Children and Adolescents with Treatment-Resistant Depression Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a The Treatment of Children and Adolescents with Treatment-Resistant Depression clinical trial. Test subjects typically receive the most effective healthcare possible for their The Treatment of Children and Adolescents with Treatment-Resistant Depression condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > The Treatment of Children and Adolescents with Treatment-Resistant Depression  The Treatment of Children and Adolescents with Treatment-Resistant Depression
The Treatment of Children and Adolescents with Treatment-Resistant Depression
For Condition: Bipolar Disorder
Status: Completed
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: This study seeks to learn about brain function in adolescents with depression and to determine whether adding lithium carbonate to antidepressant medication can reduce depression in children and adolescents. Functional magnetic resonance imaging (fMRI) and magnetic resonance spectroscopy (MRS) will examine brain chemistry and function.
Details: The participants may or may not have taken a selective serotonin reuptake inhibitor (SSRI) (such as paroxetine (Paxil), sertraline (Zoloft) or fluoxetine (Prozac)) to treat their depression. The participants and their parents are interviewed both individually and together with questions about the child's general mood, degree of nervousness, and behavior and how family members are doing. Children and adolescents will have a physical examination, blood tests, and intelligence and memory evaluations. Tests include standardized questions and tasks that involve looking at pictures, remembering things, testing reaction times, and making simple choices. Participants spend time in a, mock MRI scanner, to become comfortable with the procedure. Participants and their parents meet weekly for 2 weeks with a psychologist or psychiatrist for sessions. Those who remain depressed after these two sessions will begin study medication. Those who are not currently taking an SSRI will be offered paroxetine. Those already taking an SSRI will be randomly assigned to receive either lithium or a placebo (non-active pill) in addition to the SSRI. Treatment continues for 8 weeks. During this time, the participant and parent meet with the doctor once a week and complete written and oral evaluations. Blood will be drawn before medication begins and at the end of the 8-week treatment. Participants will have additional blood taken after 1 week on medication to help in deciding whether dose adjustment is needed. Additional blood tests might be needed later on to ensure that the dose is correct. Those who improve after 8 weeks will continue treatment at NIH until responsibility for their care can be assume by an outside physician. Program staff will help in facilitating referrals to physicians who will monitor the medication after the child leaves the study.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: All subjects Age: 9 to 17. Consent: can give consent/assent. IQ: All subjects will have IQ greater than 70. Severity Criterion: CDRS greater than 39. Impairment: All subjects will have a CGAS less than 60. SUBJECTS WITH A RESISTANT MDD: Diagnosis: Current Diagnosis of Major Depression. Treatment Resistant:At least six-weeks continual use of an SSRI, the last two of which are at high dose by the research team; CGI-S greater than 2 confirmed by observation during an additional two weeks (at least 8-weeks total duration). MEDICATION-FREE MDD SUBJECTS: Diagnosis: Current Diagnosis of Major Depression Clinical Impairment: CGAS less than 60. Medication-Free: No psychotropic medications for two month period; depressed for less than 6 months. EXCLUSION CRITERIA: Any medical condition that increases risk for SSRI or lithium treatment or for MRI exam. This will include screening for standard MRI scanning contraindications such as metallic implants or pacemakers. Pregnancy. Current use of any psychoactive substance beyond ab SSRI; current suicidal ideation; current diagnosis of attention deficit hyperactivity disorder (ADHD) of sufficient severity to require pharmacotherapy. Current diagnoses: Tourette's Disorder, OCD, post-traumatic stress disorder, conduct disorder. Past or current history of mania, psychosis, or pervasive developmental disorder. Long-Term SSRI Treatment: Subjects who have been receiving an SSRI medication for 12 wks or longer upon entry into the observational phase of the study will not be eligible for participation.
Total Enrollment: 90
Location and Contact Information:
National Institute of Mental Health (NIMH)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 020108; 02-M-0108
Study Start Date: January 14, 2002
Record last reviewed: March 3, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00029640
Other Bipolar Disorder Studies:
1. Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients with Bipolar Depression
2. Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects during the Maintenance Phase of Bipolar Illness
3. Seroquel plus Mood Stabilizer Compared to Placebo plus Mood Stabilizer in the Maintenance of Bipolar I Disorder
4. Study of Aripiprazole in Patients with a history of Bipolar Disorder
5. Olanzapine Versus Placebo in the Treatment of Mania in Adolescents with Bipolar I Disorder
Related Studies:
Other Bipolar Disorder Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
The Treatment of Children and Adolescents with Treatment-Resistant Depression
|
|
|
|
|
|
|
|
